EQS-News: ABIVAX / Key word (s): Annual Results Abivax Announces Full Year 2024 Financial Results 24.03.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement.

Based on the currently available funds and the expected reimbursement of the research tax credits (CIR) from 2024 in the second half of 2025 amounting to EUR 5.7M, Abivax expects to be able to finance ...

Almost half of people who died with inflammatory bowel disease (IBD) died prematurely, according to a study published in the ...

If you have Crohn's disease or ulcerative colitis, a clinical trial may be an option for you. Clinical trials are necessary ...

Millennials, also known as Generation Y, are the demographic group that comes after Generation X and before Generation Z.

When 30-year-old Ella Rhian set off on a dream vacation across Vietnam and Bali, she never imagined a simple meal would alter ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

New research reveals that specialized gut bacteria convert bile acids into powerful healing compounds, offering hope for ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Body mass index did not impact the safety and efficacy of etrasimod in patients with ulcerative colitis, according to 2 studies.

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...